Work With Data
Profile
user

Embertx

Updated: 47d ago

Embertx is a company. It is a private company in New York, the United States. It was founded in 2010 and its current CEO is Joseph Hernandez. It is part of the Health Care sector, specifically in the Biotechnology industry.

Key facts

plus See more facts

Extract data

Download datasets about Embertx:

dataset Dataset of stocks from Embertx:

Embertx is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in New York and 3,456,808 companies in our database.

Talking Points

  • Ember Therapeutics is a clinical stage therapeutic company focusing on Bone Morphogenetic Protein-7 (BMP-7) and its role in Osteoarthritis (OA) and organ fibrosis, including Chronic Kidney Disease (CKD) and Alport’s Syndrome.
  • Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.